中华微生物学和免疫学杂志
中華微生物學和免疫學雜誌
중화미생물학화면역학잡지
CHINESE JOURNAL OF MICROBIOLOGY AND IMMUNOLOGY
2015年
3期
207-212
,共6页
赵玮%陈小琴%万昕%程慈%林喆%冯东举%姚堃%陈云
趙瑋%陳小琴%萬昕%程慈%林喆%馮東舉%姚堃%陳雲
조위%진소금%만흔%정자%림철%풍동거%요곤%진운
鼻咽癌%EB病毒%潜伏膜蛋白2A%单核增生性李斯特菌%肿瘤疫苗
鼻嚥癌%EB病毒%潛伏膜蛋白2A%單覈增生性李斯特菌%腫瘤疫苗
비인암%EB병독%잠복막단백2A%단핵증생성리사특균%종류역묘
Nasopharyngeal carcinoma%Eepstein-barr virus%Latent membrane protein 2A%Liste-ria monocytogenes%Tumor vaccine
目的:构建含有EB病毒潜伏膜蛋白2A(LMP2A)的减毒单核增生性李斯特菌重组疫苗(Lmdd-LMP2A),并检测其抑瘤效应,旨在为鼻咽癌的免疫治疗提供新的思路及理论依据。方法将EBV-LMP2A基因克隆入李斯特菌穿梭载体p1565中,再将重组穿梭载体p1565-LMP2A电转化至减毒单核增生性李斯特菌株Lmdd感受态细胞中,得到重组疫苗Lmdd-LMP2A。进而对HLA-A2转基因小鼠皮下接种CNE-1/HLA-A2/LMP2A鼻咽癌细胞株,建立皮下荷瘤鼠模型。利用尾静脉注射法接种李斯特菌疫苗免疫荷瘤鼠并检测其特异性CTL诱导情况及抑瘤效应。结果成功构建了重组减毒李斯特菌鼻咽癌疫苗Lmdd-LMP2A,该疫苗高度减毒,安全性较好且稳定表达LMP2A蛋白并诱导特异性T细胞免疫应答。荷瘤鼠抑瘤模型结果表明,与对照组相比,Lmdd-LMP2A能明显的抑制肿瘤生长。并且,Lmdd-LMP2A免疫组也能延长小鼠的荷瘤生存期,均显示了该种重组疫苗的有效抑瘤价值。结论成功构建的减毒重组李斯特菌疫苗Lmdd-LMP2A,可以在确保安全性的同时发挥良好的特异性抗肿瘤效应,对于肿瘤治疗具有潜在的临床意义。
目的:構建含有EB病毒潛伏膜蛋白2A(LMP2A)的減毒單覈增生性李斯特菌重組疫苗(Lmdd-LMP2A),併檢測其抑瘤效應,旨在為鼻嚥癌的免疫治療提供新的思路及理論依據。方法將EBV-LMP2A基因剋隆入李斯特菌穿梭載體p1565中,再將重組穿梭載體p1565-LMP2A電轉化至減毒單覈增生性李斯特菌株Lmdd感受態細胞中,得到重組疫苗Lmdd-LMP2A。進而對HLA-A2轉基因小鼠皮下接種CNE-1/HLA-A2/LMP2A鼻嚥癌細胞株,建立皮下荷瘤鼠模型。利用尾靜脈註射法接種李斯特菌疫苗免疫荷瘤鼠併檢測其特異性CTL誘導情況及抑瘤效應。結果成功構建瞭重組減毒李斯特菌鼻嚥癌疫苗Lmdd-LMP2A,該疫苗高度減毒,安全性較好且穩定錶達LMP2A蛋白併誘導特異性T細胞免疫應答。荷瘤鼠抑瘤模型結果錶明,與對照組相比,Lmdd-LMP2A能明顯的抑製腫瘤生長。併且,Lmdd-LMP2A免疫組也能延長小鼠的荷瘤生存期,均顯示瞭該種重組疫苗的有效抑瘤價值。結論成功構建的減毒重組李斯特菌疫苗Lmdd-LMP2A,可以在確保安全性的同時髮揮良好的特異性抗腫瘤效應,對于腫瘤治療具有潛在的臨床意義。
목적:구건함유EB병독잠복막단백2A(LMP2A)적감독단핵증생성리사특균중조역묘(Lmdd-LMP2A),병검측기억류효응,지재위비인암적면역치료제공신적사로급이론의거。방법장EBV-LMP2A기인극륭입리사특균천사재체p1565중,재장중조천사재체p1565-LMP2A전전화지감독단핵증생성리사특균주Lmdd감수태세포중,득도중조역묘Lmdd-LMP2A。진이대HLA-A2전기인소서피하접충CNE-1/HLA-A2/LMP2A비인암세포주,건립피하하류서모형。이용미정맥주사법접충리사특균역묘면역하류서병검측기특이성CTL유도정황급억류효응。결과성공구건료중조감독리사특균비인암역묘Lmdd-LMP2A,해역묘고도감독,안전성교호차은정표체LMP2A단백병유도특이성T세포면역응답。하류서억류모형결과표명,여대조조상비,Lmdd-LMP2A능명현적억제종류생장。병차,Lmdd-LMP2A면역조야능연장소서적하류생존기,균현시료해충중조역묘적유효억류개치。결론성공구건적감독중조리사특균역묘Lmdd-LMP2A,가이재학보안전성적동시발휘량호적특이성항종류효응,대우종류치료구유잠재적림상의의。
Objective To prepare an attenuated Listeria vaccine Lmdd-LMP2A expressing the Ep-stein-Barr virus latent membrane protein 2A ( EBV-LMP2A) and evaluate its specific anti-tumor effects on nasopharyngeal carcinoma.Methods The gene fragment encoding EBV-LMP2A was amplified by PCR analysis and then subcloned into the shuttle vector p1565.PCR restriction enzyme digestion and DNA se-quencing were performed to identify the recombinant shuttle vector p1565-LMP2A.The p1565-LMP2A vector was then transformed into competent strains of the attenuated Listeria monocytogenes ( Lmdd) .The recombi-nant attenuated Listeria vaccine strain Lmdd-LMP2A was verified by Western blot assay.The histological sections of spleen and liver tissues were stained by Haematoxylin and eosin ( H&E) for analysis of inflamma-tion.A tumor-bearing HLA-A2 transgenic mouse model was established by subcutaneous injection of CNE-1/HLA-A2/LMP2A nasopharyngeal carcinoma cell line.The prepared Lmdd-LMP2A vaccine was inoculated into the mice via tail intravenous injection for the evaluation of specific CTL induction and the in vivo anti-tumor effects.Results The shuttle vector p1565-LMP2A and the recombinant attenuated Listeria vaccine strain Lmdd-LMP2A with stable expression of LMP2A protein were successfully constructed.The immunized mice showed mild inflammations with no structural damage and necrosis as indicated by H&E staining.The growth of tumors in tumor-bearing HLA-A2 transgenic mice was significantly inhibited by the immunization of Lmdd-LMP2A vaccine as compared with mice without inoculation.The survival time of mice was prolonged with the immunization of Lmdd-LMP2A vaccine.Conclusion The prepared attenuated Listeria vaccine Lm-dd-LMP2A showed specific anti-tumor effects with the safety advantage, suggesting the possibility of using it for anti-tumor therapy in clinic.